/** Title: Insecticides India Q1 FY27: Premium mix up, monsoon delays hit volumes */

Insecticides (India) Limited Q1 FY27: Premium mix improves as monsoon delays pressure sales

Insecticides (India) Limited (IIL) reported a weak start to FY27 as the crop protection season began unevenly. Consolidated revenue from operations for Q1 FY27 fell 12% year on year to INR 611.52 crore, compared with INR 691.13 crore in Q1 FY26. EBITDA declined 20% to INR 67.61 crore and profit after tax (PAT) fell 24% to INR 43.87 crore.

Management attributed the performance to a delayed and uneven monsoon, high temperatures in several regions, and a shift in channel activity that began earlier than usual. The company’s commentary indicated the demand impact was more of a deferral than a permanent loss, with expectations of improvement as rainfall and sowing activity normalize.

At the same time, the quarter also reinforced a key part of IIL’s longer-term strategy. Even with a volume decline, the company delivered gross margin expansion, supported by product mix improvement and a larger share of premium products in B2C.

Q1 FY27 performance: revenue down, margins hold up

The headline numbers reflect the seasonal disruption. Revenue contracted, and operating leverage was negative, pulling down EBITDA and PAT. However, gross profit declined only 4% year on year to INR 193.16 crore, and gross margin improved to 31.6% from 29.2%.

Management discussed sharp volatility in inputs such as solvents, plastics, emulsifiers, and other crude-linked raw materials. It also indicated that extraordinary price hikes were difficult to sustain in the market due to weak demand sentiment. Pricing action was attempted in March and April, with at least one later effort rolled back because the season was delayed.

The company also highlighted a tighter approach to inventory placement versus last year, aiming to reduce the risk of returns. In Q&A, management suggested that sales returns could be lower than the prior year, as placements were more cautious and diversified across products.

Portfolio and premiumization: mix shift continues

IIL’s investor presentation emphasizes a comprehensive crop protection portfolio and a long-running premiumization effort. Over the last three years, the company reported an increase in premium products’ share in B2C. In Q1 FY27, the premium share of B2C rose to 64% versus 58% in Q1 FY26.

This trend is consistent with the company’s FY26 portfolio positioning. For FY26, IIL disclosed category-wise sales mix of 49% insecticides, 37% herbicides, 10% fungicides, and 4% biologicals and PGR, on total turnover of INR 2,140 crore.

The company also highlighted that several of its new launches and differentiated products have become material over time. Management stated that launches from the last 5 to 6 years contribute roughly one-third of overall sales, linking the acceptance of technology-driven products to field engagement and return on investment demonstrated to farmers.

A major near-term focus is the collaboration with Corteva Agriscience. The presentation showcased products such as SPARCLE, GRANUVIA, GREEN MIX and SPINOACE. In the concall, management quantified early traction: GRANUVIA generated a little over INR 5 crore in Q1, while SPINOACE was still in the initial phase.

Management also shared FY27 expectations for these launches. GRANUVIA could reach about INR 20 crore gross sales in FY27, and SPINOACE could reach INR 10 crore plus. Combined gross sales of INR 30 to 35 crore were indicated, with net sales lower after a roughly 25% deduction.

In addition, the CFO provided some mix indicators for Q1 performance drivers. Revenue from in-licensing products rose to around INR 46 crore in Q1 FY27 from around INR 36 crore in Q1 FY26. Patented product revenue declined from INR 97 crore to INR 70 crore, driven mainly by reduced sales of Hachiman. Combination product contribution also declined from INR 134 crore to INR 98 crore.

Distribution, farmer engagement, and crop solution programs

IIL continues to position itself as a distribution-led brand builder in crop protection, backed by a wide retail footprint. The investor presentation cites 8,500 plus distributors, 70,000 plus retailers, and farmer reach of more than 75 lakh.

Management’s operational commentary reinforced this approach. During Q1, IIL conducted more than 3,600 farmer meetings, organized 600 field days, and ran 1,400 demonstrations, alongside more than 15,000 farmer visits. The stated objective was to maintain farmer connect even as the season started later than normal.

A key structured initiative is the IIL Crop Solutions (ICS) program, intended to demonstrate complete crop solutions and economics directly on farmer fields. The company stated it plans to double the number of plots from the current base, expanding across 14 states and focusing on four crops: rice, cotton, chili, and soybean. While management did not quantify incremental revenue associated with these plots, it positioned the initiative as a method to drive differentiated portfolio pull.

Digital platforms were also referenced in the presentation, including IIL 360 for field force, IIL Pariwar for distributors, and IIL Growsmart for employee learning.

Manufacturing and capital allocation: nearing the end of an investment cycle

Manufacturing is another pillar highlighted repeatedly. The presentation states installed capacity of 15,800 MTPA active ingredient and intermediates, 30,000 MTPA granules, 30,000 KLPA liquids, and 10,000 MTPA powder. It also claims about 95% in-house manufactured revenue.

During the call, management discussed ramp-up at Dahej and the ongoing Sotanala project. Dahej was described as largely commercialized, with over 70% already commercialized and the remaining 20% to 30% pending. Management also referred to product mix changes, division of herbicide and insecticide plants, and an upcoming boiler and steam capability to enable fuller utilization.

Sotanala was described as a large capex project with a total expected investment of around INR 200 crore. Management split this as about INR 50 crore for formulation and INR 150 crore for technical. It stated about INR 70 crore has been invested so far. The formulation facility is expected to commence around April-May next year, followed by technical production by Diwali, subject to schedule.

Importantly, management also provided a capital allocation signal. It stated that the company is approaching the end of the investment cycle and expects annual capex to normalize around INR 30 to 40 crore of maintenance capex after current projects are completed. This implies a shift in focus toward utilization, cash generation, and returns.

Takeaways from Q1 FY27

Q1 FY27 was shaped by weather-driven disruption and a delayed crop season, resulting in revenue and profit de-growth. However, the quarter also showed that IIL’s premiumization strategy is continuing to improve mix. Gross margin expanded to 31.6%, and premium share in B2C improved to 64%.

Management commentary suggests the company expects better execution over the remaining three quarters if the season normalizes. Near-term watch points remain the pace of demand recovery, raw material volatility, working capital improvement, and the ramp-up of expanded manufacturing capacity.

With Sotanala and residual commercialization at Dahej progressing, and with new product launches like GRANUVIA positioned as multi-year opportunities, the company’s stated focus is to convert investments and initiatives into sustainable growth, stronger cash generation, and improved capital efficiency.